Document is current

Article History

Received: 10 November 2023

Revised: 14 May 2024

Accepted: 28 May 2024

First Online: 28 June 2024

Competing interests

: Olaf Witt participated in advisory boards of Novartis, BMS, Janssen and receives research grants from BVD, Day One Therapeutics. Ina Oehme receives research grants from PreComb, BVD and Day One Therapeutics.

: Institutional Review Board Statement Zebrafish husbandry (permit number 35-9185.64/BH Hassel) and experiments (permit number 35-9185.81/G-126/15) were performed according to local animal welfare standards (Tierschutzgesetz §11, Abs. 1, No. 1) and in accordance with European Union animal welfare guidelines (EU Directive 2010/63/EU). All applicable national and institutional guidelines for the care and use of zebrafish were followed. Xenograft of tumour cell suspension was carried out in immune-compromised mice (Nod-scid IL2Rgammanull) immediately following processing (permit number G91/20). NSG mice were obtained from the laboratory breeding colony (German Cancer Research Centre). All mice were maintained in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals with approval from the Fred Hutchinson Cancer Research Centre Institutional Animal Care and Use Committee (IR no. 1457). All procedures involving animals were performed in accordance with the ethical standards of the institution.

: The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients, their legally acceptable representatives, or both (if possible) provided written informed consent. Approval for the study protocol (and any modifications thereof) was obtained from independent ethics committees and the institutional review board at each participating centre. INFORM was registered with the German Clinical Trial Register, number DRKS00007623.